Name
*
First Name
Last Name
Email
*
example@example.com
Credentials
*
1. Which best defines minimal symptom expression (MSE) in generalized myasthenia gravis?
*
a. QMG score ≤ 3
b. MG-ADL score of 0 or 1 with minimal medication side effects
c. No detectable acetylcholine receptor antibodies on serology
d. Ability to perform all activities of daily living without rest
2. What is the principal therapeutic mechanism of FcRn inhibitors in antibody-mediated diseases such as gMG?
*
a. Blocking complement activation at the neuromuscular junction
b. Depleting B cells that produce pathogenic autoantibodies
c. Preventing FcRn-mediated IgG recycling, increasing IgG catabolism and lowering pathogenic IgG levels
d. Directly neutralizing autoantibodies by binding the antigen-recognition site
3. Which statement best reflects emerging data on FcRn inhibitors in special populations with gMG?
*
a. FcRn inhibitors are effective only in AChR-positive patients and show no benefit in other antibody subtypes
b. Early data suggest efficacy in MuSK-positive and some seronegative gMG, with subgroup sizes still limited in pivotal trials
c. FcRn inhibitors are contraindicated in pediatric patients due to absent pharmacodynamic response
d. FcRn inhibitors have replaced IVIG and plasma exchange as standard of care in myasthenic crisis
Submit
Should be Empty: